Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
about
CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor ActivityIDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanomaCheckpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells.Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumorsImmunotherapy for the treatment of breast cancer.Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.Immunosenescence and cancer.Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy.CD4(+) T cell plasticity engenders robust immunity in response to cytokine therapy.Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses.Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research.Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis.Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.CD4+ T cell-mediated cytotoxicity eliminates primary tumor cells in metastatic melanoma through high MHC class II expression and can be enhanced by inhibitory receptor blockade.Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10.Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy.Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma.NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.Efficacy and immune activation of ipilimumab in early-stage lung cancer patients.Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
P2860
Q26782520-8B71DE8F-8B44-4BF9-98B8-8803B861435DQ33849567-DE09E400-93E5-4A99-BDA5-676F443A807EQ35071484-DA7DDD68-A8EF-4C11-93D7-2F6A03C69AE6Q36711007-333C83E7-AE47-4ED5-8D2E-FA36C5BD4AF1Q36951685-C564B0ED-2BD5-46D4-B438-A7EC64B8FE5CQ38353772-05337CFC-E9C6-4598-92DA-01668CD79F60Q38370539-04417F08-D36B-43CE-8D1B-4C3BACC37BA9Q38580545-6D1DBE3A-9654-4B88-B1F4-F838AE3C602DQ38636569-7321E9D0-304E-4846-9D8E-1486AA7D5650Q39144853-9D3494A4-1642-49B9-81DA-30BBED2C7319Q39492021-C618C286-E262-47AD-8EF0-104DC72F9058Q39833956-42C083D4-7062-40C0-9624-BE3CB3BEF640Q40448718-42563A55-00EC-427A-8877-1B785778B7A7Q42133193-595C437A-D278-40CA-A8D3-AB07634A68ECQ45765887-70814A31-3C4C-41E3-9234-51DA2E34AEA9Q47195330-F4957BC5-307D-4EDF-8C15-3F2C298A6FEEQ47225640-8E98F4A4-AFA2-47C0-A27A-02122858751CQ47625086-2E348E98-B3DA-4876-9ADD-61855949944DQ47812209-FDC4DC81-8D5E-407A-8053-8AC9FF9CECBFQ47821123-2CDFF6F5-14A5-4622-B3A8-EA8FCBCD8CC1Q49011434-C2C07CF1-27B9-4A9F-8B2E-C10B9B9CDC75Q50425077-B250A024-5DAE-4352-A4D0-B607F6CA6911Q50796572-B858402A-75DB-4E6F-B004-3E240D4EABE3Q52726999-8418F305-9304-4017-9B50-9310B89CD85FQ54945263-6A4816CC-8EDD-4FD1-94A4-8A1D9D9D0574Q55709749-5C521619-4E74-43E6-AAB3-2135ED727F54Q57057523-49EF9036-11C6-4A10-AAA6-EBDF2B88088D
P2860
Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enhancement of tumor-reactive ...... ur advanced melanoma patients.
@en
Enhancement of tumor-reactive ...... ur advanced melanoma patients.
@nl
type
label
Enhancement of tumor-reactive ...... ur advanced melanoma patients.
@en
Enhancement of tumor-reactive ...... ur advanced melanoma patients.
@nl
prefLabel
Enhancement of tumor-reactive ...... ur advanced melanoma patients.
@en
Enhancement of tumor-reactive ...... ur advanced melanoma patients.
@nl
P2093
P2860
P921
P1476
Enhancement of tumor-reactive ...... ur advanced melanoma patients.
@en
P2093
Caillian Liu
Chrisann Kyi
Daniel Hirschhorn-Cymerman
Jedd D Wolchok
Jianda D Yuan
Sacha Gnjatic
Shigehisa Kitano
Takemasa Tsuji
P2860
P304
P356
10.1158/2326-6066.CIR-13-0068
P577
2013-10-01T00:00:00Z